scholarly article | Q13442814 |
P50 | author | Gérard Socié | Q19859709 |
Jeff Szer | Q42715070 | ||
Stephanie J. Lee | Q55979666 | ||
P2093 | author name string | Shinichiro Okamoto | |
Mahmoud Aljurf | |||
Yoshiko Atsuta | |||
Navneet S Majhail | |||
Carmem Bonfim | |||
John R Wingard | |||
Maria Teresa Van Lint | |||
J Douglas Rizzo | |||
Linda J Burns | |||
Stella Davies | |||
Andre Tichelli | |||
Center for International Blood and Marrow Transplant Research (CIBMTR) | |||
European Group for Blood and Marrow Transplantation (EBMT) | |||
Naeem Chaudhri | |||
Adriana Seber | |||
American Society for Blood and Marrow Transplantation (ASBMT) | |||
Asia-Pacific Blood and Marrow Transplantation Group (APBMT) | |||
Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ) | |||
Sociedade Brasileira de Transplante de Medula Ossea (SBTMO) | |||
East Mediterranean Blood and Marrow Transplantation Group (EMBMT), | |||
P2860 | cites work | Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 |
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws | Q28240354 | ||
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective | Q28388806 | ||
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey | Q29391755 | ||
Liver transplantation for severe hepatic graft-versus-host disease: an analysis of aggregate survival data | Q30987544 | ||
Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. | Q33179317 | ||
Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment | Q33371313 | ||
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation | Q33710708 | ||
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase | Q33813443 | ||
Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. | Q34036696 | ||
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) | Q34474785 | ||
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. | Q34528330 | ||
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study | Q34554733 | ||
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning | Q34568905 | ||
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation | Q34700473 | ||
Endocrine late effects after bone marrow transplant | Q34722713 | ||
Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. | Q34963618 | ||
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation | Q35023409 | ||
Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years | Q35023468 | ||
Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment | Q35737132 | ||
Endocrine complications of high-dose therapy with stem cell transplantation | Q35763915 | ||
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study | Q35847602 | ||
Late effects after stem cell transplantation (SCT) in children--growth and hormones | Q36090236 | ||
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study | Q36141716 | ||
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transpla | Q36380493 | ||
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Wo | Q36424524 | ||
Update on ocular graft versus host disease | Q36561557 | ||
Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management | Q36585735 | ||
Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials | Q36596493 | ||
Immunobiology of allogeneic hematopoietic stem cell transplantation | Q36665305 | ||
Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation | Q36945333 | ||
Thyroid function following hematopoietic cell transplantation in children: 30 years' experience | Q37041913 | ||
Solid cancers after allogeneic hematopoietic cell transplantation | Q37082013 | ||
Iron overload in hematopoietic cell transplantation | Q37148278 | ||
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation | Q37201899 | ||
Recognizing and managing chronic graft-versus-host disease | Q37346706 | ||
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma | Q37356389 | ||
Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center | Q37704224 | ||
Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management | Q37741643 | ||
Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. | Q37781691 | ||
Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease | Q37789530 | ||
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD | Q37791005 | ||
Late complications after hematopoietic stem cell transplantation | Q37810122 | ||
Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation | Q43123519 | ||
??? | Q22306355 | ||
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation | Q43579107 | ||
Acute left ventricular failure following melphalan and fludarabine conditioning | Q43703238 | ||
Prospective evaluation of neurological complications after allogeneic bone marrow transplantation | Q43994969 | ||
Characteristics and correlates of cognitive functioning following bone marrow transplantation | Q44458858 | ||
Cerebral angiitis in four patients with chronic GVHD. | Q48406803 | ||
Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation | Q48808996 | ||
Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. | Q50733914 | ||
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. | Q51988742 | ||
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant R | Q53260982 | ||
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. | Q53537221 | ||
High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. | Q53558015 | ||
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women | Q56656398 | ||
Long-term outcome of hepatitis C infection after bone marrow transplantation | Q58034510 | ||
Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation | Q72333661 | ||
Cataract formation after bone marrow transplantation | Q72605106 | ||
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM) | Q73497707 | ||
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis | Q74242371 | ||
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial | Q74389035 | ||
Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation | Q79157140 | ||
Late cardiotoxicity after treatment for Hodgkin lymphoma | Q79374548 | ||
Chronic kidney disease in long-term survivors of hematopoietic cell transplant | Q79751158 | ||
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study | Q80151067 | ||
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation | Q80193284 | ||
Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young children | Q80993650 | ||
Regionally limited or rare infections: prevention after hematopoietic cell transplantation | Q84794963 | ||
Vaccination of hematopoietic cell transplant recipients | Q84794978 | ||
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface | Q95826686 | ||
P433 | issue | 3 | |
P921 | main subject | Australia | Q408 |
P304 | page(s) | 348-371 | |
P577 | publication date | 2011-12-13 | |
P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
P1476 | title | Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation | |
P478 | volume | 18 |
Q38545052 | A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. |
Q46921945 | A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function |
Q34267886 | Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. |
Q38777460 | Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. |
Q40718203 | Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation. |
Q92155614 | Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents |
Q38248359 | Autologous hematopoietic cell transplantation: an update for clinicians |
Q37646861 | Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents |
Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
Q89674644 | Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults |
Q36951682 | Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study |
Q26851957 | Cardiac toxicity in cancer survivors |
Q37624268 | Cardiovascular disease in survivors of hematopoietic cell transplantation. |
Q85942264 | Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes |
Q38262917 | Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. |
Q38772931 | Clinical management of genital chronic GvHD. |
Q38060559 | Clinical practice implications of immunizations after pediatric bone marrow transplant: a literature review |
Q91049108 | Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies |
Q90124938 | Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma |
Q56641541 | Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease |
Q38557591 | Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet. |
Q38797541 | Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis |
Q39026510 | Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy |
Q30240070 | Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation |
Q88426253 | Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD |
Q27021501 | Delivering care to long-term adult survivors of hematopoietic cell transplantation |
Q49570612 | Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations |
Q38079076 | Development of an evidence-based clinical guideline for age-appropriate screening, prevention, and management of bone abnormalities in children post-hematopoietic stem cell transplant |
Q54296431 | Effectiveness of long-term routine pulmonary function surveillance following pediatric hematopoietic stem cell transplantation. |
Q35859239 | Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. |
Q37577950 | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
Q92158090 | Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant |
Q38545979 | Functional hyposplenism after hematopoietic stem cell transplantation |
Q34551863 | Haematopoietic stem cell transplantation for autoimmune diseases |
Q36744037 | Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative |
Q58117403 | Hematopoietic stem cell transplantation and quality of life during the first year of treatment |
Q37107428 | High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for 'late effects' screening and preventive strategies. |
Q61798366 | High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation |
Q38797551 | How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. |
Q99241272 | Immune Reconstitution Disorders: Spotlight on Interferons |
Q89915009 | Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial |
Q37509207 | Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection |
Q90184237 | Impact of a Replacement Algorithm for Vitamin D Deficiency in Adult Hematopoietic Stem Cell Transplant Patients |
Q37460433 | Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation |
Q47565618 | International variations in the use of haematopoietic cell transplantation for haematological malignancies: the effects of national transplant indications tables and differing access to therapies |
Q88609459 | Iodine staining and p16 immunohistochemistry as a novel screening for secondary esophageal neoplasm after hematopoietic stem cell transplantation |
Q36783762 | Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report |
Q33605306 | Late cardiovascular complications after hematopoietic cell transplantation |
Q33574136 | Late effects of blood and marrow transplantation |
Q90750941 | Late infectious complications in hematopoietic cell transplantation survivors: a population-based study |
Q47780022 | Late treatment effects following bone marrow transplant: Efficacy of implementing international guidelines |
Q47743601 | Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. |
Q38798042 | Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care |
Q38667959 | Long-term complications after hematopoietic cell transplantation |
Q34749088 | Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes |
Q39002166 | Mechanistic approaches for the prevention and treatment of chronic GVHD. |
Q37104278 | Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT |
Q38933848 | Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. |
Q40442400 | Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors |
Q35762578 | National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pedia |
Q38376913 | National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report |
Q36766324 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report |
Q38374821 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes |
Q46181268 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. |
Q38405199 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report |
Q30245682 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report |
Q26787225 | Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology |
Q93040006 | Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) ret |
Q93341813 | Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo |
Q90371647 | Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT |
Q38541845 | Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management |
Q38160758 | Osteoporosis after stem cell transplantation |
Q30235173 | Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. |
Q50173239 | Palliative care during and following allogeneic hematopoietic stem cell transplantation |
Q40445423 | Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients |
Q37188807 | Prevalence of hematopoietic cell transplant survivors in the United States |
Q39098779 | Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis. |
Q36478727 | Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation |
Q48660711 | Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes. |
Q50672020 | Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres. |
Q36676908 | Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation |
Q64074914 | Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors |
Q39289010 | Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium |
Q40563365 | Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation |
Q38628809 | Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies. |
Q50104242 | Second Malignancies after Hematopoietic Stem Cell Transplantation |
Q44366982 | Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study |
Q34325244 | Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning |
Q102379465 | Secondary oral cancer following hematopoietic cell transplantation |
Q28088369 | Secondary solid cancer screening following hematopoietic cell transplantation |
Q37239517 | Sexual health in hematopoietic stem cell transplant recipients. |
Q38071930 | Surviving the cure: long term followup of hematopoietic cell transplant recipients |
Q38350270 | Survivorship after allogeneic transplantation-management recommendations for the primary care provider |
Q100750548 | Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years |
Q57477760 | Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation |
Q98195449 | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) |
Q30244617 | The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell [...] |
Q48095352 | Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes |
Q93231451 | To D or not to D: vitamin D in hematopoietic cell transplantation |
Q91329943 | Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults |
Q89840186 | Treatment and disease-related complications in multiple myeloma: Implications for survivorship |
Q26996051 | Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients |
Q33558733 | Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation |
Q36959899 | Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients |
Q58605810 | Vitamin D: is it important in haematopoietic stem cell transplantation? A review |
Search more.